<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Verapamil</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00661</strong>&#160; (APRD00335)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A calcium channel blocker that is a class IV anti-arrhythmia agent. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00661/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00661/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00661.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00661.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00661.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00661.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00661.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00661">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Iproveratril </td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr><tr><td>V&#233;rapamil</td><td>French</td><td>DCF</td></tr><tr><td>Verapamil</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>INN, BAN, USAN</td></tr><tr><td>Verapamilo</td><td>Spanish</td><td>INN</td></tr><tr><td>Verapamilum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Verapamil Hydrochloride</strong>
          <div class="cas">152-11-4</div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000534/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000534/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: DOQPXTMNIUCOSY-UHFFFAOYNA-N</li>
              <li>Monoisotopic Mass: 490.259835453</li>
              <li>Average Mass: 491.063</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000534">DBSALT000534</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Bosoptin</td><td>Bosnalijek</td></tr><tr><td>Calan</td><td>Pfizer</td></tr><tr><td>Calan SR</td><td>Pfizer</td></tr><tr><td>Covera-HS</td><td>GD Searle</td></tr><tr><td>Isoptin</td><td>Abbott</td></tr><tr><td>Isoptin SR</td><td>Abbott</td></tr><tr><td>Verelan</td><td>Alkermes</td></tr><tr><td>Verelan PM</td><td>Alkermes</td></tr><tr><td>Verisop</td><td>Gerard</td></tr><tr><td>Vermin</td><td>Ratiopharm</td></tr><tr><td>Vermine</td><td>Pharmasant</td></tr><tr><td>Verogalid</td><td>Ivax</td></tr><tr><td>Verogalid ER</td><td>Ivax</td></tr><tr><td>Verpamil</td><td>Mylan</td></tr><tr><td>Vertab</td><td>Trinity-Chiesi</td></tr><tr><td>Vetrimil</td><td>CCPC</td></tr><tr><td>Zolvera</td><td>Rosemont</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Tarka</td><td>trandolapril + verapamil hydrochloride</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anti-arrhythmia-agents">Anti-Arrhythmia Agents</a></li>
<li><a href="/mesh/vasodilator-agents">Vasodilator Agents</a></li>
<li><a href="/mesh/calcium-channel-blockers">Calcium Channel Blockers</a></li></ul></td></tr><tr><th>CAS number</th><td>52-53-9</td></tr><tr><th>Weight</th><td>Average: 454.6016<br>Monoisotopic: 454.283157714</td></tr><tr><th>Chemical Formula</th><td>C<sub>27</sub>H<sub>38</sub>N<sub>2</sub>O<sub>4</sub></td></tr><tr><th>InChI Key</th><td>SGTNSNPWRIOYBX-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,13-16H2,1-7H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile</div></td></tr><tr><th>SMILES</th><td><div class="wrap">COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Phenethylamines</td></tr><tr><th>Direct parent</th><td>Phenethylamines</td></tr><tr><th>Alternative parents</th><td>Benzyl Cyanides; Anisoles; Alkyl Aryl Ethers; Tertiary Amines; Polyamines; Nitriles</td></tr><tr><th>Substituents</th><td>phenol ether; anisole; alkyl aryl ether; tertiary amine; polyamine; carbonitrile; nitrile; ether; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the phenethylamines. These are compounds containing a phenethylamine moiety, which consists of a phenyl group substituted at the second position by an ethan-1-amine.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of hypertension, angina, and cluster headache prophylaxis.</td></tr><tr><th>Pharmacodynamics</th><td>Verapamil is an L-type calcium channel blocker that also has antiarrythmic activity. The R-enantiomer is more effective at reducing blood pressure compared to the S-enantiomer. However, the S-enantiomer is 20 times more potent than the R-enantiomer at prolonging the PR interval in treating arrhythmias.</td></tr><tr><th>Mechanism of action</th><td>Verapamil inhibits voltage-dependent calcium channels. Specifically, its effect on L-type calcium channels in the heart causes a reduction in ionotropy and chronotropy, thuis reducing heart rate and blood pressure. Verapamil's mechanism of effect in cluster headache is thought to be linked to its calcium-channel blocker effect, but which channel subtypes are involved is presently not known.</td></tr><tr><th>Absorption</th><td>90%</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>90%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Verapamil</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002887" target="_blank">Cytochrome P450 2C8</a></li>
<li><a href="/biodb/bio_entities/BE0003611" target="_blank">Cytochrome P450 2C18</a></li>
<li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li></ul></td><td><a href="/metabolites/DBMET00619">O-Desmethylverapamil (D-702)</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/130">Details</a></td></tr><tr><td>Verapamil</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002887" target="_blank">Cytochrome P450 2C8</a></li></ul></td><td><a href="/metabolites/DBMET00131">Verapamil metabolite D-617</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/131">Details</a></td></tr><tr><td>Verapamil</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002887" target="_blank">Cytochrome P450 2C8</a></li>
<li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0002362" target="_blank">Cytochrome P450 3A5</a></li>
<li><a href="/biodb/bio_entities/BE0002433" target="_blank">Cytochrome P450 1A2</a></li></ul></td><td><a href="/metabolites/DBMET00132">Norverapamil</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/132">Details</a></td></tr><tr><td>Verapamil</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002887" target="_blank">Cytochrome P450 2C8</a></li>
<li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li></ul></td><td><a href="/metabolites/DBMET00471">O-Desmethylverapamil (D-703)</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/480">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00619">O-Desmethylverapamil (D-702)</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002362" target="_blank">Cytochrome P450 3A5</a></li>
<li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET01234">Verapamil metabolite D-620</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1387">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00131">Verapamil metabolite D-617</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0002362" target="_blank">Cytochrome P450 3A5</a></li></ul></td><td><a href="/metabolites/DBMET01234">Verapamil metabolite D-620</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1388">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00131">Verapamil metabolite D-617</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01235">Verapamil metabolite PR-25</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1389">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00132">Norverapamil</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002887" target="_blank">Cytochrome P450 2C8</a></li></ul></td><td><a href="/metabolites/DBMET01236">Verapamil metabolite D-715 (PR-22)</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1390">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00132">Norverapamil</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002887" target="_blank">Cytochrome P450 2C8</a></li></ul></td><td><a href="/metabolites/DBMET01234">Verapamil metabolite D-620</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1391">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Approximately 70% of an administered dose is excreted as metabolites in the urine and 16% or more in the feces within 5 days. About 3% to 4% is excreted in the urine as unchanged drug.</td></tr><tr><th>Half life</th><td>2.8-7.4 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>LD<sub>50</sub>=8 mg/kg (i.v. in mice)</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Verapamil Action Pathway</td><td>Drug action</td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="snp-fx"><thead><tr><th>Interacting Gene/Enzyme</th><th>SNP RS ID</th><th>Allele name</th><th>Defining change</th><th>Effect</th><th>Reference(s)</th></tr></thead><tbody><tr><td>Beta-1 adrenergic receptor<br>Gene symbol: ADRB1<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P08588" target="_blank">P08588 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs1801253" target="_blank">rs1801253 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>G &gt; C</td><td>Better response to drug therapy</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/22192668" target="_blank" title='# Parvez B, Chopra N, Rowan S, Vaglio JC, Muhammad R, Roden DM, Darbar D: A common beta1-adrenergic receptor polymorphism predicts favorable response to rate-control therapy in atrial fibrillation. J Am Coll Cardiol. 2012 Jan 3;59(1):49-56. doi: 10.1016/j.jacc.2011.08.061. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22192668'>22192668 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9371</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.6323</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.738</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.7874</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.9056</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.855</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Inhibitor
        </td>
        <td>0.6259</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8029</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8706</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7657</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9553</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9071</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9026</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.796</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9181</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.8393
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.6463
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          3.4137 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.7687
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.8188
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Mylan pharmaceuticals inc</li>
<li>Elan drug delivery inc</li>
<li>Gd searle llc</li>
<li>Fsc laboratories inc</li>
<li>Abraxis pharmaceutical products</li>
<li>Bedford laboratories div ben venue laboratories inc</li>
<li>Hospira inc</li>
<li>International medication system</li>
<li>Luitpold pharmaceuticals inc</li>
<li>Marsam pharmaceuticals llc</li>
<li>Smith and nephew solopak div smith and nephew</li>
<li>Solopak medical products inc</li>
<li>Ranbaxy laboratories inc</li>
<li>Glenmark generics ltd</li>
<li>Ivax pharmaceuticals inc sub teva pharmaceuticals usa</li>
<li>Par pharmaceutical inc</li>
<li>Pliva inc</li>
<li>Actavis elizabeth llc</li>
<li>Heritage pharmaceuticals inc</li>
<li>Mutual pharmaceutical co inc</li>
<li>Sandoz inc</li>
<li>Warner chilcott div warner lambert co</li>
<li>Watson laboratories inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.abbott.com">Abbott Laboratories Ltd.</a></li>
<li>Advanced Pharmaceutical Services Inc.</li>
<li>Alza Corp.</li>
<li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li>Apotheca Inc.</li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.atlanticbiologicals.com">Atlantic Biologicals Corporation</a></li>
<li><a href="http://BASF%20Corp.">BASF Corp.</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.caremark.com">Caremark LLC</a></li>
<li>Comprehensive Consultant Services Inc.</li>
<li>Copley Chemical Co.</li>
<li>Dee Stevens and Son Feeder</li>
<li>Dept Health Central Pharmacy</li>
<li>Direct Dispensing Inc.</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li><a href="http://www.duramed.ca">Duramed</a></li>
<li><a href="http://www.elan.com">Elan Pharmaceuticals Inc.</a></li>
<li><a href="http://www.fsclabs.com">FSC Laboratories</a></li>
<li>GD Searle LLC</li>
<li><a href="http://www.giv.com">General Injectables and Vaccines Inc.</a></li>
<li><a href="http://www.glenmark-generics.com">Glenmark Generics Ltd.</a></li>
<li><a href="http://www.gsms.us">Golden State Medical Supply Inc.</a></li>
<li><a href="http://www.ghc.org">Group Health Cooperative</a></li>
<li><a href="http://hjharkinscompanyinc.com">H.J. Harkins Co. Inc.</a></li>
<li>Heartland Repack Services LLC</li>
<li><a href="http://www.hospira.com">Hospira Inc.</a></li>
<li>Ivax Pharmaceuticals</li>
<li>Kaiser Foundation Hospital</li>
<li>Lake Erie Medical and Surgical Supply</li>
<li>Liberty Pharmaceuticals</li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.palmettopharm.com">Palmetto Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pfizer.com">Pfizer Inc.</a></li>
<li>Pharmaceutical Utilization Management Program VA Inc.</li>
<li><a href="http://www.pharmaciaupjohn.com">Pharmacia Inc.</a></li>
<li><a href="http://www.pharmedixrx.com">Pharmedix</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.preferredpharmaceuticals.com">Preferred Pharmaceuticals Inc.</a></li>
<li>Prepackage Specialists</li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li><a href="http://www.prescript.net">Prescript Pharmaceuticals</a></li>
<li><a href="http://www.ranbaxy.com">Ranbaxy Laboratories</a></li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.sandhillspackaging.com">Sandhills Packaging Inc.</a></li>
<li>Schwarz Pharma Inc.</li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li>Talbert Medical Management Corp.</li>
<li>Tya Pharmaceuticals</li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li><a href="http://www.urlpharma.com">United Research Laboratories Inc.</a></li>
<li>Vangard Labs Inc.</li>
<li><a href="http://www.watson.com">Watson Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule, extended release</td><td>Oral</td><td></td></tr><tr><td>Liquid</td><td>Intravenous</td><td></td></tr><tr><td>Solution</td><td>Intravenous</td><td></td></tr><tr><td>Tablet</td><td>Oral</td><td></td></tr><tr><td>Tablet, extended release</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><ul><li><a data-no-turbolink="true" href="/spectra/spectra/nmr_one_d/1754">1H NMR Spectrum</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/1711">MS/MS Spectrum Quattro_QQQ 10</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/1712">MS/MS Spectrum Quattro_QQQ 25</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/1713">MS/MS Spectrum Quattro_QQQ 40</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/5476">MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 10</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/5477">MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 20</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/5478">MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 30</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/5479">MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 40</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/5480">MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 50</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/5481">MS/MS Spectrum LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) </a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/5482">MS/MS Spectrum LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) </a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/5483">MS/MS Spectrum LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) </a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/5484">MS/MS Spectrum LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) </a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/5485">MS/MS Spectrum LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) </a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/nmr_two_d/1694">[1H,13C] 2D NMR Spectrum</a></li></ul></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01193">Acebutolol</a></td><td>Increased effect of both drugs</td></tr><tr><td><a href="/drugs/DB01143">Amifostine</a></td><td>Verapamil may enhance the hypotensive effect of Amifostine. At chemotherapeutic doses of Amifostine, Verapamil should be withheld for 24 hours prior to Amifostine administration. Caution should be used at lower Amifostine doses used during radiotherapy, but routine interruption of Verapamil therapy is not recommended.</td></tr><tr><td><a href="/drugs/DB01223">Aminophylline</a></td><td>Verapamil increases the effect of theophylline</td></tr><tr><td><a href="/drugs/DB01118">Amiodarone</a></td><td>Additive bradycardic effects may occur. One case report of sinus arrest has been reported. Monitor for changes in the therapeutic effect and signs of Verapamil toxicity if Amiodarone is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB01351">Amobarbital</a></td><td>Amobarbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Amobarbital is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00701">Amprenavir</a></td><td>Amprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Amprenavir is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB01072">Atazanavir</a></td><td>Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Atazanavir is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00335">Atenolol</a></td><td>Increased effect of both drugs</td></tr><tr><td><a href="/drugs/DB01076">Atorvastatin</a></td><td>Verapamil, a moderate CYP3A4 inhibitor, may increase the serum concentration of Atorvastatin by decreasing its metabolism. Avoid concurrent use if possible or reduce lovastatin dose during concomitant therapy. Monitor for changes in the therapeutic/adverse effects of Atorvastatin if Verapamil is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00612">Bisoprolol</a></td><td>Increased effect of both drugs</td></tr><tr><td><a href="/drugs/DB01558">Bromazepam</a></td><td>Verapamil may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or a reductin in the bromazepam dose. Monitor for changes in the therapeutic and adverse effects of bromazepam if verapamil is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00490">Buspirone</a></td><td>Verapamil may increase the serum concentration of Buspirone. The likely occurs via Verapamil-mediated CYP3A4 inhibition resulting in decreased Buspirone metabolism. Monitor for changes in the therapeutic/adverse effects of Buspirone if Verpamil is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00237">Butabarbital</a></td><td>Butabarbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Butabarbital is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00241">Butalbital</a></td><td>Butalbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Butalbital is initiated, discontinued or dose changed.  </td></tr><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>Verapamil may increase the serum concentration of Carbamazepine by decreasing its metabolism. Monitor for changes in the therapeutic/adverse effects of Carbamazepine if Verapamil is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01136">Carvedilol</a></td><td>Increased effect of both drugs</td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>Clarithromycin, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Clarithromycin is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB01394">Colchicine</a></td><td>Verapamil may increase the serum concentration of Colchicine. This likely occurs via Verapamil-mediated inhibition of CYP3A4 and p-glycoprotein-mediated transport. Monitor for changes in the therapeutic/adverse effects of Colchicine if Verapamil is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00872">Conivaptan</a></td><td>Conivaptan, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Conivaptan is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>Verapamil may increase the serum concentration of cyclosporine by inhibiting CYP3A4-mediated metabolism of cyclosporine. Monitor for changes in the therapeutic/adverse effects of cyclosporine if verapamil is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB06695">Dabigatran etexilate</a></td><td>Verapamil may increase serum concentrations of the active metabolite(s) of dabigatran etexilate, resulting in an increased risk of bleeding. It is also a strong p-glycoprotein inhibitor. Therapy modification should be considered.</td></tr><tr><td><a href="/drugs/DB01264">Darunavir</a></td><td>Darunavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Darunavir is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00705">Delavirdine</a></td><td>Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Delavirdine is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB01396">Digitoxin</a></td><td>Verapamil may increase the serum concentration of Digitoxin by decreasing its metabolism and clearance. Monitor for changes in the therapeutic/adverse effects of Digitoxin if Verpamail is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00390">Digoxin</a></td><td>Verapamil may increase the serum concentration of Digoxin by decreasing its metabolism and clearance. Monitor for changes in the therapeutic/adverse effects of Digoxin if Verpamail is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00204">Dofetilide</a></td><td>Verapamil may increase the plamsa levels of Dofetilide. Increased risk of torsade de pointes. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB04855">Dronedarone</a></td><td>Verapamil is a moderate CYP3A4 inhibitor and will increase dronedarone levels 1.4-1.7 fold. Decrease doses of non-dihyropyridinic calcium-channel blocker. </td></tr><tr><td><a href="/drugs/DB00700">Eplerenone</a></td><td>This CYP3A4 inhibitor increases the effect and toxicity of eplerenone</td></tr><tr><td><a href="/drugs/DB00199">Erythromycin</a></td><td>Erythromycin, a moderate CYP3A4 inhibitor, may increase the serum concentration of veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Monitor for changes in the therapeutic/adverse effects of verapamil if erythromycin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00187">Esmolol</a></td><td>Increased effect of both drugs</td></tr><tr><td><a href="/drugs/DB01590">Everolimus</a></td><td>Concomitant administration may increase the serum concentrations of both agents. Concurrent use should be avoided. </td></tr><tr><td><a href="/drugs/DB00196">Fluconazole</a></td><td>Fluconazole may increase the serum concentration of Verapamil by decreasing Verapamil metabolism. This likely occurs via Fluconazole-mediated CYP3A4 inhibition. Monitor for changes in the therapeutic/adverse effects of Verapamil if Fluconazole is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB01319">Fosamprenavir</a></td><td>Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Fosamprenavir is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB01218">Halofantrine</a></td><td>Verapamil, a moderate CYP3A4 inhibitor, may increase the serum concentration of Halofantrine by decreasing its metabolism. Extreme caution with increased cardiac status monitoring should be used during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00619">Imatinib</a></td><td>Imatinib, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Imatinib is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB05039">Indacaterol</a></td><td>Strong inhibitors of CYP3A4 may increase levels of indacaterol. Monitor closely for adverse events. </td></tr><tr><td><a href="/drugs/DB00224">Indinavir</a></td><td>Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Indinavir is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00951">Isoniazid</a></td><td>Isoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Isoniazid is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>Itraconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Itraconazole is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>Ketoconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Ketoconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00598">Labetalol</a></td><td>Increased effect of both drugs</td></tr><tr><td><a href="/drugs/DB01356">Lithium</a></td><td>Signs of lithium toxicity</td></tr><tr><td><a href="/drugs/DB01601">Lopinavir</a></td><td>Lopinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Lopinavir is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00227">Lovastatin</a></td><td>Verapamil, a moderate CYP3A4 inhibitor, may increase the serum concentration of Lovastatin by decreasing its metabolism. Avoid concurrent use if possible or reduce lovastatin dose during concomitant therapy. Monitor for changes in the therapeutic/adverse effects of Lovastatin if Verapamil is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00474">Methohexital</a></td><td>Methohexital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Methohexital is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00849">Methylphenobarbital</a></td><td>Methylphenobarbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Methylphenobarbital is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00264">Metoprolol</a></td><td>Increased effect of both drugs</td></tr><tr><td><a href="/drugs/DB01110">Miconazole</a></td><td>Miconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Miconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00683">Midazolam</a></td><td>Verapamil may increase the serum concentration of Midazolam by decreasing its metabolism. Avoid concomitant therapy if possible or consider a dose reduction in the initial dose of Midazolam.</td></tr><tr><td><a href="/drugs/DB01203">Nadolol</a></td><td>Increased effect of both drugs</td></tr><tr><td><a href="/drugs/DB00607">Nafcillin</a></td><td>Nafcillin may decrease the serum concentration of Verapamil by increasing its metabolism via CYP3A4. Monitor for changes in the therapeutic/adverse effects of Verapamil if Nafcillin is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB01149">Nefazodone</a></td><td>Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Nefazodone is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00220">Nelfinavir</a></td><td>Nelfinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Nelfinavir is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00622">Nicardipine</a></td><td>Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Nicardipine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01580">Oxprenolol</a></td><td>Increased effect of both drugs</td></tr><tr><td><a href="/drugs/DB01303">Oxtriphylline</a></td><td>Verapamil increases the effect of theophylline</td></tr><tr><td><a href="/drugs/DB00312">Pentobarbital</a></td><td>Pentobarbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Pentobarbital is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01174">Phenobarbital</a></td><td>Phenobarbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Phenobarbital is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>Verapamil may increase the serum concentration of Phenytoin by decreasing its metabolism. Monitor for changes in the therapeutic/adverse effects of Phenytoin if Verapamil is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00960">Pindolol</a></td><td>Increased effect of both drugs</td></tr><tr><td><a href="/drugs/DB01263">Posaconazole</a></td><td>Posaconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Posaconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00457">Prazosin</a></td><td>Risk of hypotension at the beginning of therapy</td></tr><tr><td><a href="/drugs/DB00794">Primidone</a></td><td>The barbiturate, primidone, decreases the effect of the calcium channel blocker, verapamil.</td></tr><tr><td><a href="/drugs/DB00571">Propranolol</a></td><td>Increased effect of both drugs</td></tr><tr><td><a href="/drugs/DB00908">Quinidine</a></td><td>Concurrent therapy may result in increased serum levels of both agents. Both agents are CYP3A4 inhibitors and substrates. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of the agent if the other is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01369">Quinupristin</a></td><td>This combination presents an increased risk of toxicity</td></tr><tr><td><a href="/drugs/DB00243">Ranolazine</a></td><td>Verapamil, a CYP3A4 inhibitor, may increase the serum concentration of Ranolazine. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00615">Rifabutin</a></td><td>Rifabutin, a CYP3A4 inducer, may decrease the serum concentration of Verapamil by increasing its metabolism (particularly in the intestinal mucosa) and decreasing its absorption. Monitor for changes in the therapeutic/adverse effects of Verapamil if Rifabutin is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Rifampin, a CYP3A4 inducer, may decrease the serum concentration of Verapamil by increasing its metabolism (particularly in the intestinal mucosa) and decreasing its absorption. Monitor for changes in the therapeutic/adverse effects of Verapamil if Rifampin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01201">Rifapentine</a></td><td>Rifapentine, a CYP3A4 inducer, may decrease the serum concentration of Verapamil by increasing its metabolism (particularly in the intestinal mucosa) and decreasing its absorption. Monitor for changes in the therapeutic/adverse effects of Verapamil if Rifapentine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00503">Ritonavir</a></td><td>Ritonavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Ritonavir is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00073">Rituximab</a></td><td>Verapamil may increase the hypotensive effects of Rituximab. Consider withholding Verapamil therapy for 12 hours prior to Rituximab infusion. </td></tr><tr><td><a href="/drugs/DB01232">Saquinavir</a></td><td>Saquinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Saquinavir is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00418">Secobarbital</a></td><td>Secobarbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Secobarbital is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB06207">Silodosin</a></td><td>Verapamil is a moderate inhibitor of CYP3A4 and inhibits P-glycoprotein thus increasing the potential for adverse effects</td></tr><tr><td><a href="/drugs/DB00641">Simvastatin</a></td><td>Verapamil, a moderate CYP3A4 inhibitor, may increase the serum concentration of Simvastatin by decreasing its metabolism. Avoid concurrent use if possible or reduce Simvastatin dose during concomitant therapy. Monitor for changes in the therapeutic/adverse effects of Simvastatin if Verapamil is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>The calcium channel blocker, Verapamil, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Verapamil therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB00706">Tamsulosin</a></td><td>Verapamil, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Verapamil is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Telithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinblastine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Telithromycin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00342">Terfenadine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00277">Theophylline</a></td><td>Verapamil increases the effect of theophylline</td></tr><tr><td><a href="/drugs/DB00599">Thiopental</a></td><td>Thiopental, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Thiopental is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00373">Timolol</a></td><td>Additive effects of decreased heart rate and contractility may occur. Increased risk of heart block. </td></tr><tr><td><a href="/drugs/DB00932">Tipranavir</a></td><td>Tipranavir, co-administered with Ritonavir, may alter the concentration of Verapamil. Monitor for efficacy and adverse/toxic effects of Verapamil.</td></tr><tr><td><a href="/drugs/DB01036">Tolterodine</a></td><td>Verapamil may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB06212">Tolvaptan</a></td><td>Verapamil, a moderate CYP3A4 inhibitor, may increase the serum concentration of Tolvaptan. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB01030">Topotecan</a></td><td>The p-glycoprotein inhibitor, Verapamil, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Verapamil may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.</td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>The CYP3A4 inhibitor, Verapamil, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Verapamil is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. </td></tr><tr><td><a href="/drugs/DB00897">Triazolam</a></td><td>Verapamil may increase the serum concentration of Triazolam by decreasing its metabolism. Avoid concomitant therapy if possible or consider a dose reduction in the initial dose of Triazolam.</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of verapamil by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of verapamil if voriconazole is initiated, discontinued or dose changed.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Avoid excessive quantities of coffee or tea (Caffeine).</li>
<li>Avoid natural licorice.</li>
<li>Avoid taking with grapefruit juice.</li>
<li>Take with food.</li></ul></td></tr></tbody></table>